Skip to main content
Equibles
VRCA logo

VRCA · Verrica Pharmaceuticals Inc. · Metrics

Track VRCA — free

Use VRCA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VRCA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.91 -0.04 (-0.81%) At close · Sep 11
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”
View the 10-Q filed Aug 6, 2026
Market Cap
$84.35M
Shares
17.18M

VRCA metrics

63 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.91
Market cap
$84.35M

Price action

20 metrics
Price change (1W)
-7.6%
Price change (30D)
+1.9%
Price change (3M)
-17.8%
Price change (6M)
-19.5%
Price change (YTD)
-40.4%
Price change (1Y)
-2.0%
Trailing year
Price change (5Y)
—
52-week high
$9.10
52-week low
$3.28
Change from 52-week high
-45.6%
Change from 52-week low
+50.9%
Annualized volatility
94.7%
Annualized volatility (3M)
64.3%
Beta
2.2
RSI (14D)
43.4
Price vs SMA 50
-8.1%
Price vs SMA 200
-21.0%
Avg volume (3M)
62,515
Relative volume
0.9
Average dollar volume
$338,052

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
17.18M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.8×
reciprocal yield 35.7%
P / book
19.7
reciprocal yield 5.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-36.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
13.0×
reciprocal yield 7.7%
EV / revenue historical average (5Y)
13.0×
reciprocal yield 7.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
-93.6%
Trailing 12 months
Net margin
-102.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$28.38M
Net income (TTM)
−$31.18M
Trailing 12 months
Diluted EPS (TTM)
$-1.74
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.44

Growth

11 metrics
Revenue growth YoY
-53.8%
Year over year
Net income growth YoY
-6,547.5%
Revenue (TTM)
$30.32M
Trailing 12 months
EPS growth YoY
-3,200.0%
Shares change YoY
+124.5%
Year over year · more shares
Revenue CAGR (3Y)
+57.9%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-724.0%
Return on assets
-86.6%
Debt / equity
—
Current ratio
1.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
-7.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$11.20M
Total assets
$36.02M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$13.35M
Capital expenditures (TTM)
—
R&D (TTM)
$14.62M
SG&A (TTM)
$37.86M
Stock compensation (TTM)
—
R&D / revenue
48.2%
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
43
13F filer change QoQ
+4
Institutional ownership
27.1%

Short interest

3 metrics
Short interest
1.3%
Latest settlement · 1.4 days to cover
Days to cover
1.4d
Short-squeeze score
39 / 100

Insider activity

2 metrics
Net insider buying (90D)
$210,890
Insider-sentiment score
91 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1660334 CUSIP 92511W207 13F (30d) 17 filings 17 filers Visit website Investor relations